Skip to main content

Advertisement

Table 2 Characteristics of the patients with polymyositis/dermatomyositis for muscle and lung analysis

From: Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity

  PM/DM patients (n= 11)
  Muscle (n= 5) Lung (n= 6)
Number of PM/DM 2/3 3/3
Number of males/females 2/3 1/5
Age (years) 60.4 ± 5.3 59.8 ± 4.3
Duration of the disease (month) 17.6 ± 13.4 20.8 ± 13.2
Number of cases of new onset/flare 4/1 3/3
Number of antinuclear antibody-positive 1 (n = 4) 1 (n = 5)
Number of anti-Jo-1 antibody-positive 0 (n = 4) 1 (n = 5)
Serum creatinine kinase (IU/l)a 2,946.4 ± 1,195.4 141.4 ± 57.4 (n = 5)
Manual muscle testing score 54.3 ± 5.8 (n = 4) NA
Number of patients with ILD 4 6
AaDO2 with ILD NA 22.7 ± 6.6 (n = 5)
Treatment at time of biopsy   
   Untreated 4 4
   Prednisolone alone 0 2
   Prednisolone and cyclosporine 1 0
  1. Data presented as n or mean ± standard error of the mean. Antinuclear antibody was analyzed by immunofluorescence assay. The titer of anti-Jo-1 antibody was investigated by enzyme immunoassay. Although in some patients, anti-dsDNA (n = 1 and n = 2 for muscle and lung samples, respectively), anti-RNP (n = 1 and n = 2), anti-Scl-70 (n = 1 and n = 2), and anti-SS-A (n = 1 and n = 4) antibodies and rheumatoid factor (n = 2 and n = 4) were analyzed, they were all negative. AaDO2, alveolar-arterial oxygen pressure difference; ILD, interstitial lung disease; NA, not available; PM/DM, polymyositis/dermatomyositis. aNormal range: male < 197 IU/l, female < 180 IU/l.